Core Insights - Bayer's Eylea® 8mg (Aflibercept 8mg) was launched during the China International Import Expo, approved for treating neovascular age-related macular degeneration (nAMD) in May 2023, offering a more effective and longer treatment interval for patients [1][2] - The product aims to enhance patient compliance and quality of life by reducing the frequency of injections from monthly to potentially every four months based on clinical assessments [1][2] Group 1 - Eylea® 8mg provides a significant upgrade in dosage and formulation, demonstrating strong early efficacy and prolonged disease control, which alleviates the burden of frequent hospital visits for patients [1][2] - The prevalence of nAMD in China is projected to rise from 4.5 million in 2020 to 8.8 million by 2050, with a high risk of progression to legal blindness if not treated promptly [1] - Bayer emphasizes a patient-centered approach, continuously addressing unmet medical needs in the field of ophthalmology [1][2] Group 2 - Current clinical guidelines recommend anti-VEGF injections as the first-line treatment for nAMD, yet there are significant gaps in disease control and treatment adherence due to short drug efficacy and high injection frequency [2] - The clinical value of Eylea® 8mg has been validated in the pivotal Phase III PULSAR study, showing comparable vision improvement with fewer injections compared to the 2mg dosage [2] - Eylea® 8mg has already commenced patient injections in several provinces in China, with expectations for broader patient access to this innovative treatment [2]